The erythropoietin-derived peptide MK-X and erythropoietin have neuroprotective effects against ischemic brain damage.

ABSTRACT: Erythropoietin (EPO) has been well known as a hematopoietic cytokine over the past decades. However, recent reports have demonstrated that EPO plays a neuroprotective role in the central nervous system, and EPO has been considered as a therapeutic target in neurodegenerative diseases such as ischemic stroke. Despite the neuroprotective effect of EPO, clinical trials have shown its unexpected side effects, including undesirable proliferative effects such as erythropoiesis and tumor growth. Therefore, the development of EPO analogs that would confer neuroprotection without adverse effects has been attempted. In this study, we examined the potential of a novel EPO-based short peptide, MK-X, as a novel drug for stroke treatment in comparison with EPO. We found that MK-X administration with rep

SUBMITTER: Yoo SJ 

PROVIDER: S-EPMC5596568 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature